Fulltext

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Uemura H 1 , Ye D 2 , Kanesvaran R 3 , Chiong E 4 , Lojanapiwat B 5 , Pu YS 6 Show all authors , Rawal SK 7 , Abdul Razack AH 8 , Zeng H 9 , Chung BH 10 , Md Yusoff NA 11 , Ohyama C 12 , Kim CS 13 , Leewansangtong S 14 , Tsai YS 15 , Liu Y 16 , Liu W 17 , van Kooten Losio M 18 , Asinas-Tan M 19

Affiliations 

  • 1 Department of Urology, Kindai University, Faculty of Medicine, Osaka-Sayama, Japan
  • 2 Fudan University Shanghai Cancer Center, Shanghai, China
  • 3 Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
  • 4 Department of Urology, National University Hospital, National University Health System, Singapore
  • 5 Division of Urology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • 6 Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
  • 7 Rajeev Gandhi Cancer Institute, New Delhi, India
  • 8 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 9 Department of Urology, West China Hospital, Sichuan University, Sichuan, China
  • 10 Department of Urology and Urological Science Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
  • 11 Urology Department, Institute Urology and Nephrology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 12 Department of Urology, Hirosaki University Graduate School of Medicine, Japan
  • 13 Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  • 14 Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 15 Department of Urology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan
  • 16 Department of Global Epidemiology, Johnson & Johnson, New Brunswick, NJ, USA
  • 17 Janssen Research and Development, Shanghai, China
  • 18 Janssen Medical Affairs, Asia Pacific, Sydney, Australia
  • 19 Janssen Medical Affairs, Asia Pacific, Singapore
BJU Int, 2020 04;125(4):541-552.
PMID: 31868997 DOI: 10.1111/bju.14980

Abstract

OBJECTIVES: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry.

PATIENTS AND METHODS: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient-reported quality of life was prospectively assessed using the European Quality of Life-five Dimensions, five Levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017.

RESULTS: Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co-morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ-5D-5L visual analogue score was 74.6-79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen-deprivation therapy (either orchidectomy or luteinising hormone-releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy).

CONCLUSION: In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow-up period; prospective follow-up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications